Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea Clinical Trial

Official title:

Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05339243
• Other study ID #: ADM/211001/BLE/IBS
• Status: Completed
• Phase: N/A
• Start date: April 21, 2022
• Est. completion date: January 13, 2023

Study information

• Verified date: September 2023
• Source: Vedic Lifesciences Pvt. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: January 13, 2023
• Est. primary completion date: January 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females aged =18 to = 65 years.

2. Participants diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) as per ROME IV criteria: i) Recurrent abdominal pain on average at least one day/week in the last three months, associated with two or more of the following criteria: Related to defecation Associated with a change in stool frequency (increase/decrease in frequency). Associated with a change in the form (appearance) of stool. ii) History of abnormal bowel movements predominantly diarrhoea (>25% of bowel movement categorised as stool form type 6 or 7 (diarrhoea) and <25% as stool form type 1 or 2 constipation) on BSFS).

3. Participants with an IBS-SSS score = 175.

4. Participants who test negative for COVID-19 by Rapid Antigen Lateral Flow Test Device.

5. Participants who can comply and perform the procedures as per the protocol (consumption of study medications, biological sample collection procedures, and study visit schedule). Female participants who are willing to use acceptable contraceptives during the study duration.

6. Participants who are literate enough to understand the purpose of the study and their rights.

7. Participants who are able to give written informed consent and are willing to participate in the study.

Exclusion Criteria:

1. Participants diagnosed with anxiety as assessed by STAI-AD S- anxiety subscale score = 40.

2. Gluten and/or lactose intolerant individuals.

3. Abnormal Thyroid Stimulating Hormone (TSH) value which is (< 0.4 to > 4.2 mIU/L).

4. Participants with uncontrolled type II diabetes mellitus defined as random blood glucose (RBG) > 199 mg/dL or fasting blood glucose (FBG) >125 mg/dL.

5. Participants with a body mass index (BMI) = 30 kg/m2.

6. Presence of uncontrolled hypertension defined as systolic blood pressure (SBP) = 140 mm Hg and/or diastolic blood pressure (DBP) = 90 mm Hg.

7. Participants with a history of intake of antibiotics (Rifaximin, metronidazole, or any other), other probiotics, prebiotics, synbiotic, proton pump inhibitors, acid sequestrants (cholestyramine, Bile colestipol), FODMAP diet, and histamine H2- receptor antagonists/H2 blockers within six weeks prior to the screening day.

8. Participants with a history of daily intake of antidepressants (Tricyclic antidepressants, Selective serotonin reuptake inhibitors (SSRIs), and Selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs)), clonidine, otilonium bromide, asimadoline, eluxadoline, diphenoxylate, antispasmodics including mebeverine and pinnaverium and anticholinergics within two weeks before the screening day.

9. Participants with a history of bariatric surgery or surgical resection of the stomach, small intestine, or large intestine.

10. Participants showing signs of bile acid malabsorption (BAM), as evident from the history of green colour or foul odour of the stool during the last month.

11. Participants with a history of or complications from malignant tumours.

12. Participation in other clinical trials in the last 90 days prior to screening

13. Active smokers or using any form of smokeless tobacco.

14. Participants with substance abuse problems (within two years) defined as:

15. Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine dependence.

16. High-risk drinking as defined by the consumption of four or more alcohol-containing beverages on any day or eight or more alcohol- containing beverages per week for women and five or more alcohol-containing beverages on any day or 15 or more alcohol- containing beverages per week for men.

17. Participants having clinically significant illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and/or any inflammatory disorder, tumour, and other gastrointestinal diseases.

Related Conditions & MeSH terms

• Diarrhea
• Irritable Bowel Syndrome
• Irritable Bowel Syndrome With Diarrhea
• Syndrome

Intervention

Other:
• ES 1
Two capsules orally once daily after breakfast for 84 days
• HT ES1
Two capsules orally once daily after breakfast for 84 days
• Placebo
Two capsules orally once daily after breakfast for 84 days

Locations

Country	Name	City	State
India	Apex Gastro Clinic and Hospital	Ahmedabad	Gujarat
India	Gastroplus, Digestive disease centre	Ahmedabad	Gujarat
India	Dr. Sudhir Maharshi clinic	Jaipur	Rajasthan
India	Jaipur National University Institute for Medical Science & Research Centre	Jaipur	Rajasthan
India	Dr. Sanjeev Khanna clinic	Mumbai	Maharashtra
India	Shantaee Nursing Home	Mumbai	Maharashtra
India	Stress test clinic	Mumbai	Maharashtra
India	Aman Hospital and research centre	Vadodara	Gujarat

Sponsors (1)

Lead Sponsor	Collaborator
Vedic Lifesciences Pvt. Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Irritable Bowel Syndrome-Symptom Severity Scale	To determine the efficacy of investigational products on the participants global assessment of gastrointestinal symptoms, as assessed by change in Irritable Bowel Syndrome-Symptom Severity Scale total score at the end of study from baseline compared to placebo.; Each of these 5 items is scored on a visual analogue scale from 0 to 100. Therefore, the total score on the ranges from 0 to 500. Participants are asked to respond to each question on a 100-point visual analogue scale. The higher the scores, the more will be the severity of symptoms. Participants, if required, can be categorized as having mild (75-175), moderate (175-300),; Higher the score is the worst outcome and lower the score is the betterment.	day 0, 28, 56, and 84
Secondary	Bristol Stool Form Scale	At the end of days 28, 56, and 84, the percentage of participants transitioning to normal stool consistency (as demonstrated by weekly BSFS score reported as 3, 4, or 5) compared to baseline scores will be identified to evaluate the efficacy of IP in comparison to placebo.	day 0, 28, 56, and 84
Secondary	Irritable Bowel Syndrome-Quality of Life	Quality of life as assessed by change in Irritable Bowel Syndrome-Quality of Life.; It is a 34-item questionnaire with each item rated on a 5-point scale (34-170), with increasing scores indicating the deteriorating quality of life (Appendix-III). However, to facilitate comparisons among various measures on a standardized scale, the summed scores will be transformed to a 0 - 100 scale ranging from 0 (poor quality of life) to 100 (maximum quality of life).	day 0, 28, 56, and 84
Secondary	Abdominal Pain Severity-Numeric Rating Scale score.	Abdominal pain severity as assessed by change in Abdominal Pain Severity-Numeric Rating Scale (APS-NRS) score.; score ratings include 0 - None, 1 to 3 - Mild, 4 to 6 - Moderate, 7 to 9 - Severe, and 10; = very severe.4	day 0, 28, 56, and 84
Secondary	State-Trait Anxiety Inventory-Adults score.	Mental health as assessed by change in State-Trait Anxiety Inventory-Adults (STAI-AD) score. The State-Trait Anxiety Inventory has 40 items, 20 allocated to each S-Anxiety and T-Anxiety sub-scales . The range of scores for each subtest is 20-80, the higher score indicating greater anxiety. A cut point of 39-40 has been suggested to detect clinically significant symptoms for the S-Anxiety scale	day 0, 28, 56, and 84
Secondary	Vitals - blood pressure	To evaluate the safety of IP consumption .; Normal BP ranging Systolic120 - 129 mmHg and or diastolic 80 - 84 mm Hg	day 0, 28, 56, and 84
Secondary	Gut microbiome as assessed by 16S rRNA sequencing of faecal samples.		day 0 and 84
Secondary	Vitals - Pulse Rate	Normal Pulse rate 60 - 100 bpm	day 0, 28, 56, and 84